Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL29799795 | 0.96 | KCNH2 (0.41) | KCNH2RXFP1SMN1; SMN2NPC1RAB9A | |
| Lithium Ion SCHEMBL27238876 | 0.95 | KCNH2 (0.40) | KCNH2RXFP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3974016 | 0.82 | NPC1 (0.43) | KCNH2RXFP1NPC1RAB9AKDM4E | |
| SCHEMBL1252612 | 0.80 | MAPT (0.40) | SMN1; SMN2KDM4ECA2MTNR1AMTNR1B | |
| SCHEMBL15999426 | 0.79 | POLB (0.40) | SMN1; SMN2NPC1RAB9AKDM4EGAA | |
| SCHEMBL1252235 | 0.79 | ABCB1 (0.43) | KDM4ECA2GAACHRM2MTNR1A | |
| SCHEMBL10238814 | 0.79 | CYP2C19 (0.49) | KCNH2KDM4ECHRM2LMNAMAPK1 | |
| SCHEMBL1253874 | 0.77 | CYP2D6 (0.39) | KCNH2SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL4742417 | 0.77 | KDM4E (0.42) | KCNH2RXFP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1658639 | 0.77 | KDM4E (0.42) | KCNH2RXFP1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20250270197-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-08-28 | — | — | US | disclosed |
| US-12180198-B2 | Ribocil C antibiotics effective for Gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-12-31 | — | — | US | disclosed |
| EP-3880675-B1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INT SA (CH) | 2024-11-06 | — | — | EP | disclosed |
| CN-113272302-B | Antibiotic compound, method for producing same, pharmaceutical composition containing same, and use thereof | 德彪药业国际股份公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240190872-A1 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240116911-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-04-11 | — | — | US | disclosed |
| CN-114907251-B | Method for constructing methyl heterocyclic compound by palladium-catalyzed alkyne nucleophilic methylation reaction | 大连理工大学 | 2024-03-08 | — | — | CN | disclosed |
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007053131-A2 | ACRYLAMIDE DERIVATIVES AS ANTIBIOTIC AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-05-10 | — | — | WO | disclosed |
| US-20060183908-A1 | inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-08-17 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
| EP-1608377-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | Affinium Pharmaceuticals, Inc. (CA) | 2005-12-28 | — | — | EP | disclosed |
| EP-1575951-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | Affinium Pharmaceuticals, Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004052890-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
| WO-2000076990-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | PGLS, MGAM, GMDS | KCNH2 2941/4885RXFP1 4580/4885SMN1; SMN2 4306/4885 |
| US-20060183908-A1 | inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics | AADAC, AZI2, DCXR | KCNH2 1320/4885RXFP1 4600/4885SMN1; SMN2 4813/4885 |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | MRPL21, EMG1, RRS1 | KCNH2 1363/4885RXFP1 1055/4885SMN1; SMN2 2288/4885 |
| US-20240116911-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | RPSA, RPS5, RPS2 | KCNH2 1702/4885RXFP1 2869/4885SMN1; SMN2 3296/4885 |
| US-20250270197-A1 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | RPSA, RPS5, RPS2 | KCNH2 1702/4885RXFP1 2869/4885SMN1; SMN2 3296/4885 |
| US-12180198-B2 | Ribocil C antibiotics effective for Gram-negative pathogens | RPSA, RPS5, RPS2 | KCNH2 1702/4885RXFP1 2869/4885SMN1; SMN2 3296/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | KCNH2 4319/4885RXFP1 3956/4885SMN1; SMN2 4007/4885 |
| US-20240190872-A1 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | DBI, MGAM, MGAM2 | KCNH2 3082/4885RXFP1 3488/4885SMN1; SMN2 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.